Loss of response to melatonin treatment is associated with slow melatonin metabolism.
暂无分享,去创建一个
Robert Didden | Leopold M G Curfs | R. Didden | L. Curfs | M. Smits | W Braam | I van Geijlswijk | Henry Keijzer | Marcel G Smits | H. Keijzer | I. V. van Geijlswijk | W. Braam | I. V. Geijlswijk | Henry Keijzer
[1] Seithikurippu R. Pandi-Perumal,et al. Dim light melatonin onset (DLMO): A tool for the analysis of circadian phase in human sleep and chronobiological disorders , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[2] A. Lewy,et al. Melatonin shifts human circadian rhythms according to a phase-response curve. , 1992, Chronobiology international.
[3] A. D. Rodrigues,et al. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[4] R. Didden,et al. Melatonin for Chronic Insomnia in Angelman Syndrome: A Randomized Placebo-Controlled Trial , 2008, Journal of child neurology.
[5] J. Emens,et al. Melatonin Entrains Free‐running Blind People According to a Physiological Dose‐response Curve , 2005, Chronobiology international.
[6] J. Lafitte,et al. Five novel natural allelic variants—951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)—of the human CYP1A2 gene in a French Caucasian population , 2001, Human mutation.
[7] G. Miller,et al. Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. , 2001, Biochemistry.
[8] Ncbi. National Center for Biotechnology Information , 2008 .
[9] A. Coenen,et al. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.
[10] B. Malow,et al. Melatonin for Insomnia in Children With Autism Spectrum Disorders , 2008, Journal of child neurology.
[11] R. Didden,et al. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta‐analysis , 2009, Developmental medicine and child neurology.
[12] Shufeng Zhou,et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.
[13] M. Laudon,et al. Clinical trials of controlled‐release melatonin in children with sleep–wake cycle disorders , 2000, Journal of pineal research.
[14] M. Sugama,et al. [Usefulness of melatonin for developmental sleep and emotional/behavior disorders--studies of melatonin trial on 50 patients with developmental disorders]. , 1999, No to hattatsu = Brain and development.
[15] J. Brockmöller,et al. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.
[16] J. Emens,et al. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period , 2002, Chronobiology international.
[17] T. Kamataki,et al. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[18] K. B. Heijden,et al. Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia , 2005, Journal of sleep research.
[19] G. Kerkhof,et al. Correlation between concentrations of melatonin in saliva and serum in patients with delayed sleep phase syndrome. , 1998, Therapeutic drug monitoring.
[20] Tuomas Korhonen,et al. Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin. , 2006, Basic & clinical pharmacology & toxicology.
[21] R. Hayes,et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. , 1992, Pharmacogenetics.
[22] Bruno Claustrat,et al. The basic physiology and pathophysiology of melatonin. , 2005, Sleep medicine reviews.
[23] R. Wurtman,et al. Melatonin: a sleep-promoting hormone. , 1997, Sleep.
[24] J. Fourtillan,et al. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. , 2000, Biopharmaceutics & drug disposition.
[25] T. Kamataki,et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.
[26] L. Bertilsson,et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study , 2001, Clinical pharmacology and therapeutics.
[27] R. Wurtman,et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[28] E. V. van Someren,et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.
[29] Shu-Feng Zhou,et al. Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2 , 2009, The AAPS Journal.
[30] A. J. McArthur,et al. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment , 1998, Developmental medicine and child neurology.
[31] I. Zhdanova,et al. Melatonin as a hypnotic: pro. , 2005, Sleep medicine reviews.